Fibrino
Generic Name
Tranexamic Acid
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| fibrino 500 mg capsule | ৳ 23.00 | ৳ 138.00 |
Description
Overview of the medicine
Fibrino 500 mg Capsule contains Tranexamic Acid, an antifibrinolytic agent used to prevent and treat excessive bleeding by inhibiting the breakdown of blood clots.
Uses & Indications
Dosage
Adults
For menorrhagia: 1-1.5 g (2-3 capsules) orally 2-3 times daily for 3-4 days. For other indications, dosage varies; typically 15-25 mg/kg body weight, 2-3 times daily. Max 4g daily.
Elderly
No specific dosage adjustment required unless renal impairment is present. Adjust dosage based on renal function.
Renal_impairment
Dosage should be reduced according to creatinine clearance. For example, CrCl 30-50 mL/min: 15 mg/kg twice daily; CrCl 10-30 mL/min: 15 mg/kg once daily.
How to Take
Take the capsule orally with a glass of water, with or without food. It is recommended to take it at regular intervals as prescribed by the doctor.
Mechanism of Action
Tranexamic Acid reversibly binds to the lysine binding sites on plasminogen, preventing its activation to plasmin. This inhibits fibrinolysis, thereby stabilizing blood clots and reducing bleeding.
Pharmacokinetics
Onset
Oral: 1-2 hours
Excretion
Mainly excreted unchanged in the urine (approximately 95% of the absorbed dose) within 24 hours.
Half life
Approximately 2-3 hours
Absorption
Rapidly absorbed from the gastrointestinal tract (30-50% bioavailability). Peak plasma concentration reached within 3 hours.
Metabolism
Minimally metabolized; less than 5% is metabolized.
Side Effects
Contraindications
- •Hypersensitivity to Tranexamic Acid or any component of the formulation
- •Active intravascular clotting
- •History of thrombosis or thromboembolic disease
- •Severe renal impairment (due to accumulation risk)
- •Subarachnoid hemorrhage (risk of cerebral edema and infarction)
- •Acquired defective color vision (as monitoring is difficult)
Drug Interactions
Oral Contraceptives / Estrogens
Increased risk of thrombosis due to additive effect on coagulation.
Thrombolytic agents (e.g., Alteplase, Streptokinase)
Antagonistic effect, reduces efficacy of thrombolytics.
Factor IX Complex Concentrates / Anti-inhibitor Coagulant Concentrates
Increased risk of thrombosis.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include nausea, vomiting, diarrhea, orthostatic symptoms (e.g., dizziness when standing up), and hypotension. Management is supportive, including gastric lavage, activated charcoal, and symptomatic treatment.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of impaired fertility or harm to the fetus. Use during pregnancy only if clearly needed and potential benefits outweigh risks. Tranexamic Acid is excreted in breast milk; caution should be exercised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture.
Availability
Pharmacies, hospitals, clinics
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Generic available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
